

Information for Healthcare Professionals:

Fosamax® (alendronate sodium) Tablets and Oral Solution

Fosamax Plus D® (alendronate sodium/cholecalciferol) Tablets

Important revisions to the ADVERSE REACTIONS section of Prescribing Information and Patient Package Insert

According to MedWatch, modifications have been made to the Adverse Reactions sections of Fosamax® and Fosamax Plus D® labeling. Revised labeling highlights post-marketing adverse experiences (asthenia, peripheral edema, joint swelling, dizziness and vertigo).

The complete MedWatch Safety Labeling Changes, including links to prescribing information and patient package insert, are available at:

<http://www.fda.gov/medwatch/SAFETY/2006/dec06.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS Web site at http://www.spine.org/spine_safety_notices.cfm. This information is provided as a service for information and education only.